ATX : One of the cheapest Biotech on ASX

Amplia Therapuetics Limited

SOI 66.5 Mil
Mcap 6 mil
Cash 1.6 mil

ATX is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

ATX’s technology addresses a multi-$B market opportunity:
Unmet clinical need in pancreatic and ovarian cancer
Experienced team with a stellar record in drug development and partnering

Where are we now :

ATX has identified and developed two FAK inhibitors lead candidate AMP945 and amp886

Both can be used in 3 different ways
Combination with chemotherapy in cancer
Combination with Immunologically treated cancers
Monotherapy for Pulmonary , Liver and Renal Fibrosis

• ATX has established the foundation for clinical development of its FAK assets
• GMP1drug manufacture at kilogram scale
• Safety studies in two species to support clinical translation with clear evidence of safety
• Clinical trial design and establishment of relationships with Key Opinion Leaders (KOLs)
• Efficacy studies that demonstrate ATX’s molecules are highly differentiated / competitive
• Further meaningful protection of our intellectual property through new IP capture and extension of patent life out to late 2032

During 2019, ATX established collaborations with clinical KOLs in Australia and Internationally
Multiple opportunities for innovative and cost-effective clinical trials of ATX’s FAK inhibitors in both cancer patients and healthy volunteers to support a range of indications
Rapid pathway to Phase II studies internationally in key cancer indications (pancreatic and ovarian cancer)

We already know that AMP945 is a highly selective inhibitor of FAK
AMP945 has a very ‘clean’ kinome profile
As expected, AMP945 was shown to be much more selective for FAK with very Fewer off-target effects

Appointment of Professor Timpson who leads the Invasion and Metastasis Lab at the Garvan Institute of Medical Research and is a world leader in FAK biology. As a member of Amplia’s SAB, Professor Timpson will contribute his advice and experience to the design of the Company’s planned clinical studies so that they are designed with the very latest understanding of FAK biology in mind.

Platinum International Healthcare Fund, one of Australia’s leading biotechnology investors invested in ATX in last capital raising at 7c

Where are we going :

• Initiation of the first clinical trials of AMP945
• Further pre-clinical development to support the clinical evaluation of AMP886
• Pharma business development activity around ATX’s core assets
• Completion of IND-enabling studies that, subject to regulatory approvals, will support a rapid Phase II oncology combination therapy

At 4.5 mil EV , ATX is the cheapest oncology related Biotech on ASX. Big institutional investor , Platinum Asset fund invested in ATX in last CR. Great management team and highly successful BOD are behind this little gem. There are a lot of mergers and acquisitions are also taking place in this area of drug discovery.

IMO , ATX will reward some wonderful returns to patient investors who are willing to hold it for next 12 to 18 months. If it will go up 1000 % from here , It will still be 60 mil mcap .Subject to phase 1 completion , IMO ATX got a potential to deliver 1000 % returns .

ALL IMO

DYOR

Peace !